A comparison of three 67/68Ga-labelled exendin-4 derivatives for β-cell imaging on the GLP-1 receptor: the influence of the conjugation site of NODAGA as chelator

EJNMMI Research

Volumn 4, Issue 1, 2014, Pages 1-10

  Jodal, Andreas ^a   Lankat Buttgereit, Brigitte ^b   Brom, Maarten ^c   Schibli, Roger ^a,d   Béhé, Martin ^a  

^a ETH Zurich   (Switzerland)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ETH ZURICH   (Switzerland)

Author keywords

Exendin 4; GLP 1 receptor; Insulinoma; PET; SPECT; cell imaging

Indexed keywords

EXENDIN 4; GALLIUM 67; GALLIUM 68; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL CULTURE; CIRCULAR DICHROISM; GENETIC TRANSFECTION; GLUCOSE BLOOD LEVEL; IC50; IMAGE ANALYSIS; IN VITRO STUDY; INSULINOMA; INTERNALIZATION; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84903419975     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/s13550-014-0031-9     Document Type: Article

References (27)

1. Ito T, Igarashi H, Jensen RT: Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances.Best Pract Res Clin Gastroenterol 2012, 26:737–753.
2. Rostambeigi N, Thompson GB: What should be done in an operating room when an insulinoma cannot be found?Clin Endocrinol 2009, 70:512–515.
3. Raffel A, Krausch MM, Anlauf M, Wieben D, Braunstein S, Klöppel G, Röher H-D, Knoefel WT: Diffuse nesidioblastosis as a cause of hyperinsulinemic hypoglycemia in adults: a diagnostic and therapeutic challenge.Surgery 2007, 141:179–184.
4. Banerjee I, Avatapalle B, Padidela R, Stevens A, Cosgrove KE, Clayton PE, Dunne MJ: Integrating genetic and imaging investigations into the clinical management of congenital hyperinsulinism.Clin Endocrinol 2013, 78:803–813.
5. Böttger TC, Junginger T: Is preoperative radiographic localization of islet cell tumors in patients with insulinoma necessary?World J Surg 1993, 17:427–432.
6. Shin JJ, Gorden P, Libutti SK: Insulinoma: pathophysiology, localization and management.Futur Oncol 2010, 6:229–237.
7. Boukhman MP, Karam JM, Shaver J, Siperstein AE, DeLorimier AA, Clark OH: Localization of insulinomas.Arch Surg 1999, 134:818–822.
8. Saudek F, Brogren C, Manohar S: Imaging the beta-cell mass: why and how.Rev Diabet Stud 2008, 5:6–12.
9. Defronzo RA: From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.Diabetes 2009, 58:773–795.
10. Christ E, Wild D, Ederer S, Béhé M, Nicolas G, Caplin ME, Brändle M, Clerici T, Fischli S, Stettler C, Ell PJ, Seufert J, Gloor B, Perren A, Reubi JC, Forrer F: Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study.Lancet Diabetes Endocrinol 2013, 8587:1–8.
11. Wu Z, Todorov I, Li L, Bading JR, Li Z, Nair I, Ishiyama K, Colcher D, Conti PE, Fraser SE, Shively JE, Kandeel F: In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40-Exendin-4 by targeting GLP-1 receptor.Bioconjug Chem 2011, 22:1587–1594.
12. Brom M, Oyen WJG, Joosten L, Gotthardt M, Boerman OC: 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.Eur J Nucl Med Mol Imaging 2010, 37:1345–1355.
13. Wicki A, Wild D, Storch D, Seemayer C, Gotthardt M, Behe M, Kneifel S, Mihatsch MJ, Reubi J-C, Mäcke HR, Christofori G: [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.Clin Cancer Res 2007, 13:3696–3705.
14. Yim C-B, Mikkola K, Fagerholm V, Elomaa V-V, Ishizu T, Rajander J, Schlesinger J, Roivainen A, Nuutila P, Solin O: Synthesis and preclinical characterization of [(64)Cu]NODAGA-MAL-exendin-4 with a N(ε)-maleoyl-l-lysyl-glycine linkage.Nucl Med Biol 2013, 40:1006–1012.
15. Kirkpatrick A, Heo J, Abrol R, Goddard WA: Predicted structure of agonist-bound glucagon-like peptide 1 receptor, a class B G protein-coupled receptor.Proc Natl Acad Sci U S A 2012, 109:19988–19993.
16. Kim TH, Jiang HH, Lim SM, Youn YS, Choi KY, Lee S, Chen X, Byun Y, Lee KC: Site-specific PEGylated Exendin-4 modified with a high molecular weight trimeric PEG reduces steric hindrance and increases type 2 antidiabetic therapeutic effects.Bioconjug Chem 2012, 23:2214–2220.
17. Jin C-H, Chae SY, Son S, Kim TH, Um KA, Youn YS, Lee S, Lee KC: A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.J Control Release 2009, 133:172–177.
18. Al-Sabah S, Donnelly D: The primary ligand-binding interaction at the GLP-1 receptor is via the putative helix of the peptide agonists.Protein Pept Lett 2004, 11:9–14.
19. In’t Veld P, Marichal M: The Islets of Langerhans. Volume 654. Dordrecht: Springer Netherlands; 2010:1–19.
20. Mikkola K, Yim C-B, Fagerholm V, Ishizu T, Elomaa V-V, Rajander J, Jurttila J, Saanijoki T, Tolvanen T, Tirri M, Gourni E, Béhé M, Gotthardt M, Reubi JC, Mäcke H, Roivainen A, Solin O, Nuutila P: (64)Cu- and (68)Ga-labelled [Nle (14), Lys (40)(Ahx-NODAGA)NH 2]-exendin-4 for pancreatic beta cell imaging in rats.Mol Imaging Biol 2013, 16:255–263.
21. Clarke ET, Martell AE: Stabilities of the Fe(III), Ga(III) and In(III) chelates of N, N’, N”-triazacyclononanetriacetic acid.Inorganica Chim Acta 1991, 181:273–280.
22. Gotthardt M, Van Eerd-Vismale J, Oyen WJG, De Jong M, Zhang H, Rolleman E, Maecke HR, Behe M, Boerman O: Indication for different mechanisms of kidney uptake of radiolabeled peptides.J Nucl Med 2007, 48:596–601.
23. Son S, Chae SY, Kim CW, Choi YG, Jung SY, Lee S, Lee KC: Preparation and structural, biochemical, and pharmaceutical characterizations of bile acid-modified long-acting exendin-4 derivatives.J Med Chem 2009, 52:6889–6896.
24. Wild D, Béhé M, Wicki A, Storch D, Waser B, Gotthardt M, Keil B, Christofori G, Reubi JC, Helmut RM: [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.J Nucl Med 2006, 47:2025–2033.
25. Brom M, Joosten L, Oyen WJG, Gotthardt M, Boerman OC: Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas.Contrast Media Mol Imaging 2012, 7:160–166.
26. Wild D, Wicki A, Mansi R, Béhé M, Keil B, Bernhardt P, Christofori G, Ell PJ, Mäcke HR: Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.J Nucl Med 2010, 51:1059–1067.
27. Gotthardt M, Lalyko G, Van Eerd-Vismale J, Keil B, Schurrat T, Hower M, Laverman P, Behr TM, Boerman OC, Göke B, Béhé M: A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents.Regul Pept 2006, 137:162–167.